Endocrine Abstracts

Introduction: U-300 insulin glargine has been used as a concentrated form of glargine. Skin and subcutaneous tissue disorders (eg, rash, pruritus, and urticaria) have been reported with insulin glargine. But to our knowledge, maculopapular rash has not been reported with use of U-300 insulin glargine. We present a patient with type 1 diabetes mellitus(DM) developing maculopapular rash after initiation of U-300 glargine insulin.Case Report: 37 year-old fe...